DNTH
HEALTHCAREDianthus Therapeutics Inc.
AI Insight
What's Moving DNTH Today?
No stock-specific AI insight has been generated for DNTH yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$17.11$96.50
$87.53
Fundamentals
Market Cap$4.8B
P/E Ratio—
EPS$-4.23
Dividend Yield—
Dividend / Share—
ROE-22.7%
Profit Margin—
Debt / Equity—
Trading
Volume969K
Avg Volume (10D)—
Shares Outstanding54.7M
DNTH News
24 articles- Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsightYahoo Finance·Jun 18, 2026
- DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?Yahoo Finance·Jun 17, 2026
- Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks LingerYahoo Finance·Jun 15, 2026
- DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study ResultsStocktwits·Jun 12, 2026
- Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest HitYahoo Finance·Jun 10, 2026
- Stocks Settle Sharply Lower on Escalating Middle East TensionsBarchart·Jun 10, 2026
- Stocks Resume Decline as Chipmakers and AI Companies FallBarchart·Jun 10, 2026
- Stocks Fall on Weakness in Tech and Trucking CompaniesBarchart·Jun 10, 2026
- Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) NarrativeYahoo Finance·Jun 10, 2026
- Enterprise value of Dianthus Therapeutics, Inc. – XETR:87ETradingView·Jun 6, 2026
- Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product PipelineYahoo Finance·Jun 5, 2026
- DNTH: Multiple pivotal trials advance with key data and strong cash runway supporting growthTradingView·Jun 3, 2026
- Dianthus Therapeutics Inc (DNTH): FDA Makes Trials EasierYahoo Finance·Jun 3, 2026
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 2, 2026
- Dianthus Therapeutics to Participate in Two Investor ConferencesYahoo Finance·May 26, 2026
- Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic DiseasesYahoo Finance·May 19, 2026
- Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems BullishMotley Fool·May 18, 2026
- Assessing Dianthus Therapeutics (DNTH) Valuation After LBL-047 Autoimmune Focus Partnership And Capital RaiseYahoo Finance·May 18, 2026
- Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock RallyThe Motley Fool·May 17, 2026
- LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and DermatomyositisGlobeNewswire Inc.·May 6, 2026
- Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 5, 2026
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial ResultsYahoo Finance·May 5, 2026
- Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000The Motley Fool·Apr 19, 2026
- Dianthus Therapeutics CFO Sells $9.5 Million in StockThe Motley Fool·Apr 6, 2026
All 24 articles loaded
Price Data
Open$86.41
Previous Close$87.53
Day High$88.97
Day Low$84.61
52 Week High$96.50
52 Week Low$17.11
52-Week Range
$17.11$96.50
$87.53
Fundamentals
Market Cap$4.8B
P/E Ratio—
EPS$-4.23
Dividend Yield—
Dividend / Share—
ROE-22.7%
Profit Margin—
Debt / Equity—
Trading
Volume969K
Avg Volume (10D)—
Shares Outstanding54.7M
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—